Seventy percentage of patients who receive paclitaxel have diffuse, refractory myalgias, and arthralgias. Based on anecdotal reports, this study explored whether loratadine, an antihistamine, palliates these symptoms.
Methods:
The medical records of postoperative ovarian and patients with endometrial cancer were studied, as these patients are routinely prescribed paclitaxel. Records were screened for patients who received paclitaxel and loratadine concurrently.
Results:
Forty patients are the focus of this report. Eight had paclitaxel-induced myalgias and arthralgias and then took loratadine; of these, 6 (75%; 95% confidence interval: 35%, 97%) manifested evidence of symptom improvement: “She did experience some migrating generalized body aches and pains…but this has resolved.” Of those already receiving loratadine but with no myalgias and arthralgias, only 11 of 32, or 34% (95% confidence interval: 19%, 53%), developed myalgias and arthralgias (in contrast to the previously reported symptom rate of 70%). No adverse events were clearly attributed to loratadine.
Conclusion:
These preliminary data support further study of loratadine for paclitaxel-induced myalgias and arthralgias.
MiuraSMaemondoMIwashimaA, et al.A phase II study of carboplatin plus weekly paclitaxel with bevacizumab for elderly patients with non-squamous non-small-cell lung cancer (NEJ016). Invest New Drugs. 2017;35(2):227–234.
2.
ZhangPYinYMoH, et al.Better pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: a randomized phase 2 trial. Oncotarget. 2016;7(37):60647–60656.
3.
VaidyaAPLittellRKrasnerCDuskaLR. Treatment of uterine papillary serous carcinoma with platinum-based chemotherapy and paclitaxel. Int J Gynecol Cancer. 2006;16(suppl. 1):267–272.
4.
SongTZhangXFangMZhaoRWuS. Long-term results of definitive concurrent chemoradiotherapy using paclitaxel plus oxaliplatin in unresectable locally advanced esophageal cancer: a prospective phase II trial. Cancer Med. 2016;5(12):3371–3377.
5.
RadesDManigLJanssenSSchildSE. Concurrent chemotherapy improves the overall survival of patients irradiated for locally recurrent bladder cancer. Anticancer Res. 2017;37(3):1485–1488.
6.
NishioSTakekumaMTakeuchiS, et al.Phase 1 study of veliparib with carboplatin and weekly paclitaxel in Japanese patients with newly diagnosed ovarian cancer. Cancer Sci. 2017;108(11):2213–2220.
7.
ChiuNChiuLChowR, et al.Taxane-induced arthralgia and myalgia: a literature review. J Oncol Pharm Pract. 2017;23(1):56–67.
8.
LoprinziCLReevesBNDakhilSR, et al.Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1. J Clin Oncol. 2011;29(11):1472–1478.
9.
MoulderSLHolmesFATolcherAW, et al.A randomized phase 2 trial comparing 3-hour versus 96-hour infusion schedules of paclitaxel for the treatment of metastatic breast cancer. Cancer. 2010;116(4):814–821.
10.
FernandesRMazzarelloSHuttonB, et al.Taxane acute pain syndrome (TAPS) in patients receiving taxane-based chemotherapy for breast cancer-a systematic review. Support Care in Cancer. 2016;24(8):3633–3650.
11.
RowinskyEKChaudhryVForastiereAA, et al.Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting. J Clin Oncol. 1993;11(10):2010–2020.
12.
PachmanDRDockterTZekanPJ, et al.A pilot study of minocycline for the prevention of paclitaxel-associated neuropathy: ACCRU study RU221408I. Support Care Cancer. 2017;25(11):3407–3416.
13.
JatoiAGrudemMEDockterTJ, et al.A proof-of-concept trial of protein kinase C iota inhibition with auranofin for the paclitaxel-induced acute pain syndrome. Support Care Cancer. 2017;25(3):833–838.
14.
ShindeSSSeislerDSooriG, et al.Can pregabalin prevent paclitaxel-associated neuropathy?—An ACCRU pilot trial. Support Care Cancer. 2016;24(2):547–553.
15.
MarkmanMKennedyAWebsterKKulpBPetersonGBelinsonJ. Use of low-dose oral prednisone to prevent paclitaxel-induced arthralgias and myalgias. Gynecol Oncol. 1999;72(1):100–101.
16.
NguyenVHLawrenceHJ. Use of gabapentin in the prevention of taxane-induced arthralgias and myalgias. J Clin Oncol. 2004;22(9):1767–1769.
17.
JacobsonSDLoprinziCLSloanJA, et al.Glutamine does not prevent paclitaxel-associated myalgias and arthralgias. J Support Oncol. 2003;1(4):274–278.
18.
FujiwaraHUrabeTUedaK, et al.Prevention of arthralgia and myalgia from paclitaxel and carboplatin combination chemotherapy with Shakuyaku-kanzo-to. Gan to Kagaku Ryoho. 2000;27(7):1061–1064.
19.
GelmonKEisenhauerEBryceC, et al.Randomized phase II study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancer. J Clin Oncol. 1999;17(10):3038–3047.
20.
RickOBeyerJSchwellaNSchubartHSchleicherJSiegertW. Assessment of amifostine as protection from chemotherapy-induced toxicities after conventional-dose and high-dose chemotherapy in patients with germ cell tumor. Ann Oncol. 2001;12(8):1151–1155.
MartoniAZamagniCGhekaAPannutiF. Antihistamines in the treatment of taxol-induced paroxystic pain syndrome. J Nati Cancer Inst. 1993;85(8):676.
23.
ElyMRRomeroSASieckDCMangumJELuttrellMJHalliwillJR. A single dose of histamine-receptor antagonists before downhill running alters markers of muscle damage and delayed-onset muscle soreness. J Appl Physiol (Bethesda, Md: 1985). 2017;122(3):631–641.
24.
JaggiASKaurGBaliASinghN. Pharmacological investigations on mast cell stabilizer and histamine receptor antagonists in vincristine-induced neuropathic pain. Naunyn-Schmiedebergs Archi Pharmacol. 2017;390(11):1087–1196.
25.
GavioliEAbramsM. Prevention of granulocyte-colony stimulating factor (G-CSF) induced bone pain using double histamine blockade. Support Care Cancer. 2017;25(3):817–822.
26.
GaoWZanYWangZJHuXYHuangF. Quercetin ameliorates paclitaxel-induced neuropathic pain by stabilizing mast cells, and subsequently blocking PKCepsilon-dependent activation of TRPV1. Acta Pharmacol Sin. 2016;37(9):1166–1177.
27.
SharafoddiniADubinJAMaslowDMLeeJ. A new insight into missing data in the intensive care unit patient profiles: observational study. JMIR Med Inform. 2019;7(1):e11605.
28.
FosterJCLe-RademacherJGFelicianoJL, et al.Comparative “nocebo effects” in older patients enrolled in cancer therapeutic trials: observations from a 446-patient cohort. Cancer. 2017; 123(21):4193–4198.
29.
HalyardMYJatoiASloanJA, et al.Does zinc sulfate prevent therapy-induced taste alterations in head and neck cancer patients? Results of phase III double-blind, placebo-controlled trial. Int J Radiat Oncol Biol Phys. 2007; 67(5):1318–1322.
